Lai C H, Lin T S, Soong Y K, Chen H F
Department of Obstetrics and Gynecology, Chang Gung Memorial Hospital, Taiwan, Republic of China.
Gynecol Oncol. 1989 Nov;35(2):193-8. doi: 10.1016/0090-8258(89)90042-5.
Three hundred and sixty-eight cases of invasive cervical cancer (stage IB through early stage IIB) were treated with radical abdominal hysterectomy and bilateral pelvic lymphadenectomy at Chang Gung Memorial Hospital. Of these patients, 172 were classified postoperatively as a high-risk group after surgical-pathological assessment of tumor extent. Among these high-risk patients, 40 received adjuvant chemotherapy with cisplatin, vinblastine, and bleomycin (PVB), 38 received adjuvant radiotherapy, and 79 refused adjuvant treatment. The 3-year cumulative disease-free survival rate was 91.6% for the low-risk group and 59.7% for those at high risk. Among patients in the high-risk group, the 3-year survival rate was 75.0% for patients treated with adjuvant chemotherapy and 46.8% for those not treated with adjuvant therapy (P less than 0.05). The preliminary results of this pilot study showed a significant activity of adjuvant chemotherapy, which warrants further investigation of its role in the treatment of cervical cancer.
长庚纪念医院对368例浸润性宫颈癌（IB期至IIB早期）患者进行了根治性腹式子宫切除术及双侧盆腔淋巴结清扫术。在这些患者中，经手术病理评估肿瘤范围后，有172例术后被归类为高危组。在这些高危患者中，40例接受了顺铂、长春碱和博来霉素（PVB）辅助化疗，38例接受了辅助放疗，79例拒绝辅助治疗。低危组的3年累积无病生存率为91.6%，高危组为59.7%。在高危组患者中，接受辅助化疗的患者3年生存率为75.0%，未接受辅助治疗的患者为46.8%（P<0.05）。这项初步研究的结果显示辅助化疗具有显著疗效，这值得进一步研究其在宫颈癌治疗中的作用。
